Hints and tips:
...Roche has agreed to buy InterMune, the US biotech company, for $8.3bn in the latest example of the feverish deal activity sweeping the pharmaceuticals sector....
...Centerview’s other high-profile pharmaceuticals deals in the last two years include Salix’s $14.5bn sale to Valeant; Intermune’s $8.3bn sale to Roche; Idenix’s $3.85bn sale to Merck & Co last year; and Onyx...
...InterMune bought by Roche for $8.3bn and Cubist acquired for $9.5bn by Merck are other examples of big pharma delivering big paydays to biotech investors in the past year....
...However, people familiar with the matter said GSK was not preparing a bid for InterMune. InterMune and Sanofi did not respond to requests for comment. GSK and Goldman Sachs declined to comment....
...Similar factors were behind deals such as Roche’s $8.3bn takeover of InterMune and Merck’s acquisition of Cubist and Idenix in two further multibillion-dollar transactions last year....
...Swiss drug company Roche bought InterMune, which focuses on pulmonary treatments, for $8.3bn in August....
...Last month, Roche snapped up the privately owned Austrian biotech group, Dutalys for $489m, and earlier last year splashed out $8.3bn on the US biotech company, InterMune....
...A second legal action has been brought against the agency by InterMune, a Californian biotech company. The European and US pharmaceutical industry bodies have lodged supportive pleas....
...Boehringer Ingelheim of Germany filed for information on InterMune’s products. Both rivals were developing similar compounds....
...The Securities and Exchange Commission and the justice department have continued to investigate trading by SAC in shares of Weight Watchers, InterMune and four other stocks, according to people familiar...
...As previously reported, federal investigators examining SAC are looking into trading in stocks including Weight Watchers, InterMune, Elan, Wyeth and Dell....
...Drugmaker InterMune plunged 75 per cent to $11.38, making it one of the biggest fallers in the Russell 2000, a small-cap index, on news that it failed to win US regulatory approval for a lung treatment that...
...InterMune, a drugmaker that makes a lung disease treatment, rose 1.4 per cent to $46.44 as a company filing revealed that Steven Cohen, the founder of SAC Capital Advisors, a hedge fund that manages about...
...InterMune, a maker of a treatment for a deadly lung disease, jumped 65.6 per cent to $38.59 following a favourable recommendation by a US Food and Drug Administration panel to introduce the drug....
International Edition